在訂立浦發銀行結構性存款產品協議時，就浦發銀行結構性存款產品協議項下產品的認購金額而 言，一項或多項適用百分比率（定義見上市規則第 14.07 條）超過 5%但均低於 25%，故根據上市 規則第 14 章，该交易構成本公司之須予披露的交易，須遵守上市規則第 14 章有關申報及公告之 規定，惟獲豁免遵守獨立股東批准之規定。 概述 於二零二四年十月十日，本公司與浦發銀行訂立浦發銀行結構性存款產品協議，同意以日常營運產 生的自有閑置資金向浦發銀行認購金額為人民幣 2.00 億元的結構性存款產品。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 須予披露的交易 認購浦發銀行結構性存款產品 認購結構性存款產品 於二零二四年十月十日，本公司與浦發銀行訂立浦發銀行結構性存款產品協議，同意以日常營運 產生的自有閑置資金向浦發銀行認購總金額為人民幣 2.00 億元的結構性存款產品。 上市規則的涵義 在浦發銀行結構性存款產品協議項下，實際年化收益率如下情況計算： | 觀察價 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 須予披露的交易 認購中國銀行結構性存款產品 認購結構性存款產品 近日，本公司與中國銀行訂立中國銀行結構性存款產品協議，同意以 A 股公開發行所得暫時閑置 募集資金向中國銀行認購金額為人民幣 1.80 億元的結構性存款產品。 上市規則的涵義 在訂立中國銀行結構性存款產品協議時，就中國銀行結構性存款產品協議項下產品的認購金額而 言，一項或多項適用百分比率（定義見上市規則第 14.07 條）超過 5%但均低於 25%，故根據上市 規則第 14 章，该等交易構成本公司之須予披露的交易，須遵守上市規則第 14 章有關申報及公告 之規定，惟獲豁免遵守獨立股東批准之規定。 概述 近日，本公司與中國銀行訂立中國銀行結構性存款產品協議，同意以 A 股公開發行所得暫時閑置募 集資金向中國銀行認購金額為人民幣 1.80 億元的結構性存款產品。 - 1 - 中國銀行結構性存款產品協議 本公司與中國銀行訂立之結構性存款產品協議的主要 ...

海姆泊芬为全球首个针对鲜红斑痣治疗的光动力药物，是集新药靶、新化合 物和新适应症于一体的新药。作为第二代光敏剂，海姆泊芬有着化合物结构稳定、 光毒作用低等特点，其用于鲜红斑痣治疗被收入人民卫生出版社《皮肤性病学》 （第九版）教科书中。海姆泊芬光动力疗法治疗鲜红斑痣具有疗效确切、病灶消 退均匀、代谢迅速、避光期短、瘢痕发生率低、治愈后极少复发等显著优势。作 为国家 1.1 类新药，注射用海姆泊芬（商品名：复美达®）已于 2017 年在中国大 上海复旦张江生物医药股份有限公司自愿披露 关于注射用海姆泊芬治疗鲜红斑痣的美国Ⅱ期临床试验 完成首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海复旦张江生物医药股份有限公司（以下简称"公司"）研发的用于治疗 鲜红斑痣的注射用海姆泊芬美国注册项目（即 F0026 项目）II 期临床试验近日于 美国成功完成首例受试者入组。现将相关情况公告如下： 1 / 2 股票代码：688505 股票简称：复旦张江 编号：临 2024-033 陆地区正式上市销售。2024 年上半年 ...

股票代码：688505 股票简称：复旦张江 公告编号：临 2024-032 上海复旦张江生物医药股份有限公司 关于参加 2024 年半年度制药及生物制品专场 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2024 年 9 月 14 日（周六）16:00 前通过邮件（ir@fd-zj.com）及 电话、传真等形式将需要了解和关注的问题提前提供给公司。公司将在文字互动 环节对投资者普遍关注的问题进行回答。 上海复旦张江生物医药股份有限公司（以下简称"公司"）已于 2024 年 8 月 13 日于上海证券交易所网站（www.sse.com.cn）披露了公司 2024 年半年度报告。 为便于广大投资者全面深入地了解公司 2024 年半年度经营成果、财务状况及发 展理念，公司参与了由上海证券交易所主办的科创板 2024 年半年度制药及生物 制品专场集体业绩说明会，此次活动将采用线上文字互动的方式举行，投资者可 登录上海证券交易所上证路演中心（http://roadshow.ssei ...

Financial Performance - Revenue for the first half of 2024 was RMB 408.12 million, a decrease of 21.94% compared to RMB 522.83 million in the same period last year[6]. - Net profit attributable to shareholders for the first half of 2024 was RMB 70.47 million, representing a 2.97% increase from RMB 68.44 million in the previous year[6]. - The company's operating income for the reporting period was 408,123,863 yuan, a decrease of 21.94% from 522,827,706 yuan in the same period last year[62]. - The company reported a net profit of RMB 70,473,064 for the six months ended June 30, 2024, compared to a net profit of RMB 68,437,509 for the same period in 2023, reflecting a growth of approximately 2.99%[162]. - The sales revenue from the product Aira® decreased by 9.37% compared to the same period last year[57]. - The sales revenue from the product Liboduo® declined by 45.83% year-on-year, significantly impacting the overall revenue of the group[57]. - The sales revenue from the product 复美达® increased by 36.17% compared to the previous year[58]. Research and Development - The company's R&D expenditure accounted for 38.06% of revenue, an increase of 15.38 percentage points from 22.68% in the same period last year[7]. - The total R&D investment for the period was approximately CNY 155.33 million, representing a 30.98% increase compared to the previous period[28]. - The company filed for 17 new patents during the reporting period, with 3 patents granted, bringing the total granted patents to 96[27]. - The company has ongoing clinical trials for multiple innovative drugs, including a new compound for treating bladder cancer and a targeted therapy for triple-negative breast cancer, both at advanced stages of research[34]. - The company is committed to developing drugs that address unmet clinical needs, ensuring a balance between innovative and generic drug development[33]. - The company has made significant progress in its R&D pipeline, with several projects nearing completion of clinical trials[34]. - The company has established a nanotechnology platform aimed at enhancing drug solubility and bioavailability, with its liposomal formulation, Liboduo®, launched in August 2009[24]. Market Position and Strategy - The company operates in the biopharmaceutical sector, focusing on innovative research, development, manufacturing, and marketing[11]. - The company aims to maximize economic benefits by developing differentiated products that meet clinical needs while maintaining competitive advantages[20]. - The company is strategically focusing on expanding its market presence and enhancing its product offerings in response to competitive pressures and market dynamics[57]. - The company is exploring new sales models to address common challenges in the current marketing environment and improve patient access to treatments[36]. - The company is adopting a cautious and conservative approach to R&D expense capitalization, considering the risks and challenges associated with innovative drug development[57]. Financial Health - The total assets as of June 30, 2024, were RMB 2,848.70 million, a decrease of 0.97% from RMB 2,876.69 million at the end of the previous year[6]. - Total liabilities as of June 30, 2024, were RMB 491.27 million, down from RMB 518.12 million at the end of the previous year[6]. - The company has a conservative financial policy, focusing on centralized management of funds and regular assessments of asset liquidity[68]. - The company has no significant investment or capital expenditure plans as of June 30, 2024[68]. - The company has a long-term equity investment net value of RMB 279,219,000, with a significant stake of RMB 226,503,000 in Handu Pharmaceutical, representing 7.95% of total assets[73]. Clinical Trials and Innovations - The company received approval for Phase II clinical trials for its hydrochloride amine pentanoic acid granules for breast cancer surgery visualization in January 2024[26]. - The company is conducting a Phase I clinical study for its anti-Trop2 antibody conjugate SN38 for advanced solid tumors, with results published on ASCO's website[26]. - The company has developed a range of products including cytokines, fusion proteins, monoclonal antibodies, and antibody-drug conjugates (ADCs) based on its gene engineering technology platform, which has become feasible for industrialization as the company expands[21]. - The company is advancing clinical trials for ALA granules in breast-conserving surgery for breast cancer[46]. - The company is also advancing intraoperative molecular imaging (IMI) technology for real-time tumor visualization during surgeries, which could improve surgical outcomes[42]. Corporate Governance and Compliance - The audit committee reviewed the financial statements for the six months ending June 30, 2024, and confirmed compliance with applicable accounting standards and the Hong Kong Listing Rules[109]. - The company has fully complied with the requirements for independent non-executive directors as per the Hong Kong Listing Rules during the reporting period[113]. - The company believes that having the same person serve as both Chairman and CEO is beneficial for its current stage of development, despite the deviation from the corporate governance code[111]. - The company has not purchased, sold, or redeemed any of its listed securities during the six months ending June 30, 2024[114]. Environmental Responsibility - The company invested RMB 797,700 in environmental protection during the reporting period[115]. - The company has established an environmental protection mechanism and has not faced any administrative penalties related to environmental issues during the reporting period[115]. - The company has implemented measures for air pollution control, adhering to the Shanghai industrial waste gas emission standards[115]. - The company has established a comprehensive energy-saving and water-saving performance management system, setting specific targets for each department to enhance resource utilization and reduce waste[119]. Shareholder Information - The company plans to issue a total of 38 million restricted shares under the incentive plan, representing approximately 3.67% of the total shares issued as of June 30, 2024[88]. - The board proposed an interim dividend of RMB 0.02 per share for the six months ending June 30, 2024, totaling RMB 20,731,442 based on 1,036,572,100 shares issued[69]. - The interim dividend distribution for A shares is approximately RMB 14,211,224, while for H shares it is about RMB 6,520,000[69]. - The company distributed dividends of RMB 0.05 and RMB 0.07 per share for the fiscal years ending December 31, 2020, and December 31, 2022, respectively[90].

上海复旦张江生物医药股份有限公司 自愿披露关于注射用 FDA018 抗体偶联剂用于治疗三阴性乳腺癌 股票代码：688505 股票简称：复旦张江 编号：临 2024-031 1 / 2 该药物 III 期临床试验为评价其在 TNBC 患者中的有效性、安全性、药代动 力学特征和免疫原性的随机、对照临床试验。截至本公告披露日，该药物研究已 完成首例受试者入组。 三、 风险提示 由于医药产品具有高科技、高风险、高附加值的特点，药品从临床前研究、 临床试验到商业化的周期长、环节多，容易受到一些不确定性因素的影响。敬请 广大投资者谨慎决策，注意防范投资风险。 Ⅲ期临床试验完成首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海复旦张江生物医药股份有限公司（以下简称"公司"）研发的注射用 FDA018 抗体偶联剂（即抗 Trop2 抗体偶联 SN38，以下简称"该药物"）用于治 疗三阴性乳腺癌（TNBC）的药物Ⅲ期临床研究（以下简称"该研究"）于近日 完成首例受试者入组。 一、 药物的相关情况 该药物由针对人滋养层 ...

上海复旦张江生物医药股份有限公司 关于核心技术人员离职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海复旦张江生物医药股份有限公司（以下简称"公司"或"复旦张江"）核 心技术人员张一帆先生因个人原因申请离职。离职后，张一帆先生将不再担任公 司任何职务； 张一帆先生在公司任职期间作为发明人申请的专利所有权均归属于公司 及子公司所有，不存在涉及职务发明的纠纷或潜在纠纷的情形；张一帆先生的离 职不会对公司的研发能力、持续经营能力和核心竞争力产生重大不利影响，不会 影响公司现有核心技术及研发项目的工作开展； 根据公司发展战略、经营策略、结构优化调整等因素综合考虑，公司本 次暂不新增其他核心技术人员。 一、核心技术人员离职的具体情况 公司核心技术人员张一帆先生因个人原因于近日向公司提出离职申请。离职 后，张一帆先生不再担任公司任何职务。公司对张一帆先生任职期间为公司发展 所做出的努力和贡献表示感谢。 股票代码：688505 股票简称：复旦张江 编号：临 2024-030 （三）保密情况 根据公司与张一帆先 ...

重要内容提示： 每股现金红利 0.02 元（含税） 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2024/8/29 | 2024/8/30 | 2024/8/30 | H 股股东的现金分红有关情况详见本公司 2024 年 8 月 12 日于香港联交所网 站（www.hkex.com.hk）发布的相关公告。 一、 通过分配方案的股东大会届次和日期 证券代码：688505 证券简称：复旦张江 公告编号：临 2024-029 上海复旦张江生物医药股份有限公司 2024 年半年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司于 2024 年 6 月 27 日召开的 2023 年度股东周年大会已审议通过就 2024 年中期利润分配方案提请股东大会授权公司董事会在符合利润分配的条件下制定 具体分配方案，该利润分配预案已经公司第八届董事会第七次会议审议通过。 二、 分配方案 1. 发放年度：2024 年半年度 2. 分派对象： 截至股权登记日下午上 ...

Financial Performance - The company's revenue for the first half of 2024 was RMB 408.12 million, a decrease of 21.94% compared to RMB 522.83 million in the same period last year[6]. - Net profit attributable to shareholders for the first half of 2024 was RMB 70.47 million, representing a 2.97% increase from RMB 68.44 million in the previous year[6]. - The net cash flow from operating activities for the first half of 2024 was RMB 27.65 million, a significant recovery from a negative cash flow of RMB 108.75 million in the same period last year[6]. - The total assets as of June 30, 2024, were RMB 2,848.70 million, a decrease of 0.97% from RMB 2,876.69 million at the end of the previous year[6]. - The company's total liabilities as of June 30, 2024, were RMB 2,357.42 million, slightly down from RMB 2,358.56 million at the end of the previous year[5]. - The net assets attributable to shareholders were RMB 2,356.54 million, a minor decrease of 0.04% from RMB 2,357.55 million at the end of the previous year[6]. - The overall operating income of the group has decreased compared to the previous year due to the underperformance of key products[61]. - The group reported a total operating income of ¥408,123,863, a decrease of 21.94% from ¥522,827,706 in the same period last year[64]. - The total comprehensive income attributable to shareholders was RMB 70.48 million, slightly down from RMB 70.61 million in the previous year[146]. Research and Development - The company's R&D expenditure accounted for 38.06% of its operating revenue, an increase of 15.38 percentage points compared to 22.68% in the same period last year[7]. - R&D expenses totaled CNY 155,330,149, an increase of 30.98% compared to the previous year[30]. - The company is focusing on innovative research and development in biomedicine, aiming to become a leader in the industry by addressing clinical treatment gaps[42]. - The company has established advanced technology platforms including gene engineering, photodynamic technology, and nanotechnology, focusing on differentiated competition and maximizing economic benefits[21]. - The company aims to enhance the research and registration of gene engineering technology projects that have entered clinical stages, targeting the commercialization of gene drugs[22]. - The company has filed for 17 new patents during the reporting period, with a total of 213 patents filed to date, of which 96 have been granted[29]. - The company has a strong pipeline in photodynamic therapy, with ongoing research on Ammonium Ketone Acid for treating HPV-related cervical diseases[33]. - The company is exploring new photodynamic compounds to improve efficacy and address existing limitations in treatment[24]. Market and Industry Trends - The Chinese pharmaceutical market is projected to grow from USD 221.4 billion in 2020 to USD 349.8 billion by 2025, reflecting a compound annual growth rate (CAGR) of 11.95%[13]. - The market for broad skin disease treatment and care in China increased from RMB 300.4 billion in 2017 to RMB 471.8 billion in 2021, with a CAGR of 11.95%[14]. - The incidence of skin diseases in China is rising, with approximately 150 million patients, highlighting a growing demand for effective treatments[14]. - The global oncology market is expected to reach USD 370 billion by 2027, driven by the introduction of new drugs and biosimilars[16]. - The Chinese market for skin disease treatments is expected to maintain a steady growth trajectory, supported by increasing health awareness and consumer spending[14]. Product Development and Innovation - The company aims to become a leader in the biopharmaceutical industry by focusing on innovative research and development[12]. - The company’s first photodynamic drug, Aira® (aminolevulinic acid), has significantly reduced the recurrence rate of genital warts compared to traditional therapies, filling a clinical gap in treating specific areas[19]. - The global first photodynamic drug for treating hemangiomas, Hemoporfin® (复美达®), was launched in 2017 and has shown high cure rates and low recurrence rates compared to traditional laser treatments[20]. - The company’s photodynamic therapy solutions have been included in major clinical treatment guidelines, indicating their recognition and acceptance in the medical community[19]. - The company has developed a photodynamic therapy platform, with key products including Ela® for treating genital warts and Fumida® for treating port-wine stains, both of which have shown significant market acceptance[23]. - The company is expanding the indications for Ela®, focusing on conditions such as cervical precancerous lesions and acne, and is conducting further research on the molecular mechanisms of photodynamic therapy[24]. - The company is focusing on antibody-drug conjugates, with a total investment of CNY 57,000,000 and significant progress in clinical research[32]. Financial Management and Strategy - The company has adopted a conservative financial policy, focusing on centralized management of funds and regular assessments of asset liquidity[67]. - The company plans to maintain liquidity and enhance overall capital returns through structured deposit investments[83]. - The company is adopting a cautious approach to R&D expenditure capitalization, considering the risks and challenges associated with innovative drug development[60]. - The company plans to pursue international registration for its marketed drugs to support its global expansion strategy[24]. - The company aims to leverage various bidding and centralized procurement opportunities to enhance the marketing capabilities of its products[61]. Corporate Governance and Compliance - The audit committee is responsible for reviewing financial reports and monitoring risk management[103]. - The financial performance for the six months ending June 30, 2024, was reviewed by the audit committee[103]. - The company adheres to applicable accounting standards and Hong Kong Listing Rules[103]. - The corporate governance framework includes various rules and regulations to ensure compliance and transparency[104]. - The company’s financial statements were approved by the board of directors on August 12, 2024, indicating ongoing governance and oversight[158]. Environmental Responsibility - The company invested RMB 797,700 in environmental protection during the reporting period[109]. - The company has established a complete management system for environmental protection, including a leadership team and annual updates to the team member list[112]. - The company has implemented carbon reduction measures, achieving a reduction of 94.92 tons of CO2 equivalent emissions[113]. - The company strictly adheres to national and local standards for pollutant emissions, including wastewater and waste gas, and has implemented comprehensive treatment measures[110]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[110].

股票代码：688505 股票简称：复旦张江 编号：临 2024-027 上海复旦张江生物医药股份有限公司 关于 2024 年中期利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每 10 股派发现金红利人民币 0.2 元（含税），公司半年度不进行转增，不 送红股； 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确； 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股派 发现金红利金额不变，相应调整分配的总额，并将另行公告具体调整情况。 一、2024年中期利润分配方案内容 本发生变动的，公司拟维持每股派发现金红利金额不变，相应调整分配的总额， 并将另行公告具体调整情况。 公司2023年度股东周年大会审议通过就该中期利润分配方案提请股东大会 授权公司董事会在符合利润分配的条件下制定具体分配方案。上述预案已经公司 董事会审议通过，实际分派的金额以公司发布的权益分派实施公告为准。 二、公司履行的决策程序 （一）董事会审核委员会意见 董事会审核委 ...